𝗧𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗼𝗳 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗥𝗡𝗔-𝗟𝗡𝗣?

Encapsulate single and multiple RNAs! mRNA, saRNA, circRNA... 👉🏻 delivered in 8-10 weeks.

📩 Reach out today

🔵 At 𝗖𝗔𝗧𝗨𝗚, we provide custom solutions for #DNA, #RNA, and #LNP projects, supporting academia and industry with formulation, research, and manufacturing

𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗠𝗶𝗹𝗮𝗻𝗼 𝗳𝗼𝗿 𝗟𝗮𝗯 𝗜𝘁𝗮𝗹𝗶𝗮? 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁!

Our colleague Cesare Di Nitto will be on site next week at LAB Italia, ready to discuss #RNA and #LNP innovations.

📅 𝗝𝘂𝗻𝗲 𝟭𝟳–𝟭𝟴
📍 𝗡𝗛 𝗠𝗶𝗹𝗮𝗻𝗼 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗖𝗲𝗻𝘁𝗿𝗲

If you’re looking for a reliable 𝗥𝗡𝗔 𝗮𝗻𝗱 𝗟𝗡𝗣 𝘀𝘂𝗽𝗽𝗹𝗶𝗲𝗿 𝗼𝗿 𝗖𝗗𝗠𝗢 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, we’d love to meet.

RNA Types in Research and Therapeutics by CATUG

RNA Types in Research and Therapeutics by CATUG

RNA Types in Research and Therapeutics by CATUG

RNA Types in Research and Therapeutics by CATUG

🧬🔬Which RNA type is right for your project?

#RNAtherapeutics offers a versatile platform for transient gene expression, gene silencing, and regulation of cellular pathways.

But not all RNAs work the same.

Discover it here: catug.bio/rna-types-rn...

Yu M, Lin L, Zhou D, Liu S. Interaction design in mRNA delivery systems. J Control Release. 2025;377:413-426. doi:10.1016/j.jconrel.2024.11.038

This review shows the relevance of designing mRNA-LNPs from a biochemical perspective, considering payload and vehicle physicochemical interactions.

🔵 𝗗𝗼𝗲𝘀 𝘆𝗼𝘂𝗿 𝗟𝗡𝗣 𝘄𝗼𝗿𝗸 𝙞𝙣 𝙫𝙞𝙩𝙧𝙤 𝗯𝘂𝘁 𝗳𝗮𝗶𝗹𝘀 𝙞𝙣 𝙫𝙞𝙫𝙤? 𝗔𝘁 𝗖𝗔𝗧𝗨𝗚 𝘆𝗼𝘂 𝗰𝗮𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝘆𝗼𝘂𝗿 𝗟𝗡𝗣 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗮𝗻 𝗲𝘅𝗽𝗲𝗿𝘁.

Image sourced from the article

3️⃣ Cholesterol analogs, PEG-lipids, and helper lipids like DOPE show highly 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝘀.
4️⃣ Polymers, peptides, and inorganic carriers demand 𝗽𝗿𝗲𝗰𝗶𝘀𝗲 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝘁𝘂𝗻𝗶𝗻𝗴.
5️⃣ 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 are redefining what’s possible.

Key ideas shared in the article:
1️⃣ Delivery efficiency is shaped by 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝘁𝗮𝘁𝗶𝗰, 𝗵𝘆𝗱𝗿𝗼𝗽𝗵𝗼𝗯𝗶𝗰, 𝗵𝘆𝗱𝗿𝗼𝗴𝗲𝗻 𝗯𝗼𝗻𝗱𝗶𝗻𝗴, π-π 𝘀𝘁𝗮𝗰𝗸𝗶𝗻𝗴, 𝗮𝗻𝗱 𝗺𝗲𝘁𝗮𝗹 𝗰𝗼𝗼𝗿𝗱𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀.
2️⃣ These forces govern 𝗲𝗻𝗰𝗮𝗽𝘀𝘂𝗹𝗮𝘁𝗶𝗼𝗻, 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴, 𝗲𝗻𝗱𝗼𝘀𝗼𝗺𝗮𝗹 𝗲𝘀𝗰𝗮𝗽𝗲, 𝗮𝗻𝗱 𝗿𝗲𝗹𝗲𝗮𝘀𝗲.

𝗬𝗼𝘂'𝗿𝗲 𝗻𝗼𝘁 𝗱𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 𝗺𝗥𝗡𝗔 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝘀𝘆𝘀𝘁𝗲𝗺𝘀. 𝗬𝗼𝘂'𝗿𝗲 𝗱𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 🧪

MengyaoYu, LixinLin, DezhongZhou and ShuaiLiu highlight a fundamental shift in mRNA delivery: 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝗮𝗹𝗼𝗻𝗲 𝗶𝘀𝗻’𝘁 𝗲𝗻𝗼𝘂𝗴𝗵, performance depends on how your carriers interact with mRNA and biological systems.

🔵 𝗔𝘁 𝗖𝗔𝗧𝗨𝗚, 𝘄𝗲 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗲 𝗶𝗻 𝗗𝗡𝗔, 𝗥𝗡𝗔, 𝗮𝗻𝗱 𝗟𝗡𝗣 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀. We support researchers from early discovery and proof-of-concept to clinical trials and commercialization. From sequence optimization to LNP formulation and GMP-grade manufacturing.

As a proud 𝗘𝗧𝗣𝗡 𝗣𝗹𝗮𝘁𝗶𝗻𝘂𝗺 𝗺𝗲𝗺𝗯𝗲𝗿, we were honored to sponsor this wonderful event.

ETPN Associacion, NANOMED Spain, and Alexandre Ceccaldi for this thoughtful and well-curated conference.

Thank you team, Cesare Di Nitto, Cristina Kim Xuan Nguyen and Alejandra Carreira.

- 𝗢𝗿𝗴𝗮𝗻-𝗼𝗻-𝗮-𝗰𝗵𝗶𝗽 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 are emerging as essential tools for early-stage validation, offering a potential alternative to animal testing. Many research groups have already integrated them into their pipelines, with others planning to follow.

- 𝗥𝗡𝗔-𝗯𝗮𝘀𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 continue to attract growing interest thanks to their versatility in vaccines, gene editing, and protein replacement strategies.

- 𝗖𝗔𝗥-𝗧 𝗮𝗻𝗱 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 are gaining ground as promising approaches for cancer treatment and beyond.

CATUG at Nanomed Europe 2025. Organized for ETPN and Nanomed Spain.

CATUG at Nanomed Europe 2025. Organized for ETPN and Nanomed Spain.

CATUG at Nanomed Europe 2025. Organized for ETPN and Nanomed Spain.

CATUG at Nanomed Europe 2025. Organized for ETPN and Nanomed Spain.

💡 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗡𝗮𝗻𝗼𝗺𝗲𝗱 𝗘𝘂𝗿𝗼𝗽𝗲𝟮𝟱 (#NME25)

- 𝗟𝗶𝗽𝗶𝗱 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀, 𝗻𝗮𝗻𝗼𝗰𝗿𝘆𝘀𝘁𝗮𝗹𝘀, 𝗮𝗻𝗱 𝗽𝗼𝗹𝘆𝗺𝗲𝗿-𝗯𝗮𝘀𝗲𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 were key topics at the event, with numerous presentations and posters showcasing innovative research focused on precision drug delivery.

- 𝗢𝗿𝗴𝗮𝗻-𝗼𝗻-𝗮-𝗰𝗵𝗶𝗽 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 are emerging as essential tools for early-stage validation, offering a potential alternative to animal testing. Many research groups have already integrated them into their pipelines, with others planning to follow.

We are excited about the opportunities ahead and look forward to advancing hashtag#RNAtherapeutics through meaningful global partnerships.

Thank you Mohamed ElSayed, Ph.D. Sissi (Xi) Lin and Tommy D. for the visit, were very happy to have you.

Lin Jin, Mengfei Sun, 冯璐雯, Weicheng (Michael) Zhang

NATi is a national initiative driving the growth of nucleic acid therapeutics in Singapore and internationally. Both parties had very insightful discussions focused on exploring potential collaboration for early stage discovery projects, followed by CATUG lab tour.

Nucleic Acid Therapeutics Initiative (NATi) and CATUG team

Collaboration between CATUG and Nucleic Acid Therapeutics Initiative (NATi) from Singapore

Nucleic Acid Therapeutics Initiative (NATi)

Nucleic Acid Therapeutics Initiative (NATi) at CATUG's facilities

𝗖𝗔𝗧𝗨𝗚 𝘄𝗲𝗹𝗰𝗼𝗺𝗲𝘀 𝗦𝗶𝗻𝗴𝗮𝗽𝗼𝗿𝗲’𝘀 𝗡𝗔𝗧𝗶 𝘁𝗼 𝗼𝘂𝗿 𝗦𝘂𝘇𝗵𝗼𝘂 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗶𝗲𝘀

Last Saturday, we had the pleasure of hosting the Nucleic Acid Therapeutics Initiative (NATi) at CATUG.

This work demonstrates how targeted LNPs are effective and selective vehicles for gene therapeutics in cancer treatment.

🔵 𝗔𝘁 𝗖𝗔𝗧𝗨𝗚, 𝘄𝗲 𝗰𝗮𝗻 𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘇𝗲, 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲 & 𝗲𝗻𝗰𝗮𝗽𝘀𝘂𝗹𝗮𝘁𝗲 𝗰𝘂𝘀𝘁𝗼𝗺 𝗗𝗡𝗔 𝗮𝗻𝗱 𝗥𝗡𝗔 𝗶𝗻𝘁𝗼 𝗟𝗡𝗣𝘀.

👉🏻 catug.bio/contractrese...

Findings:
✔️ Dual-targeted LNPs 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘂𝗽𝘁𝗮𝗸𝗲 across HER2-low, medium, and high cell lines
✔️ 𝗧𝗿𝗮𝗻𝘀𝗴𝗲𝗻𝗲 𝗲𝘅𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝘄𝗮𝘀 𝗵𝗶𝗴𝗵𝗲𝗿 than with standard LNPs.
✔️ In vivo validation confirmed 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗮𝗻𝗱 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗰𝘁𝗶𝗼𝗻 in zebrafish xenografts.

Efficient and specific delivery of nucleic acids remains a key barrier in oncology, limiting therapeutic efficacy. Claudia Lotter, Megan Anna Stierli, Ramya Deepthi Puligilla, Jörg Huwyler developed 𝗹𝗶𝗽𝗶𝗱 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 (𝗟𝗡𝗣𝘀) 𝗺𝗼𝗱𝗶𝗳𝗶𝗲𝗱 𝘄𝗶𝘁𝗵 𝘁𝘄𝗼 𝘁𝗮𝗿𝗴𝗲𝘁𝘀: 𝘁𝗿𝗮𝘀𝘁𝘂𝘇𝘂𝗺𝗮𝗯 (𝗮𝗻𝘁𝗶-𝗛𝗘𝗥𝟮) 𝗮𝗻𝗱 𝗳𝗼𝗹𝗮𝘁𝗲

Join us to explore the next generation of #RNA innovation!

Drop us a message here 👉🏻 catug.bio/contact

#NME25 𝗸𝗶𝗰𝗸𝘀 𝗼𝗳𝗳 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄!

Don’t miss our intervention at the event! Cesare Di Nitto will be presenting “𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗥𝗡𝗔 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀: 𝗺𝗥𝗡𝗔-𝗟𝗡𝗣 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗳𝗿𝗼𝗺 𝗦𝗔𝗥𝗦-𝗖𝗼𝗩-𝟮 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝘁𝗼 𝗜𝗻-𝘃𝗶𝘃𝗼 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆”, showcasing how #mRNA-#LNP systems are helping reshape the future of #vaccines and #celltherapy.

𝗔𝗿𝗲 𝘆𝗼𝘂 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗼𝗻 𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀?

Check out our brochure: lnkd.in/dKUK8Gf4

🔵 𝗔𝘁 𝗖𝗔𝗧𝗨𝗚 𝘄𝗲 𝗵𝗲𝗹𝗽 𝘆𝗼𝘂 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗲, 𝘁𝗲𝘀𝘁 𝗮𝗻𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲 𝗰𝘂𝘀𝘁𝗼𝗺 𝗺𝗥𝗡𝗔-𝗟𝗡𝗣.

• We saw several applications of #AI in cell and gene therapy, including its 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗥𝗡𝗔 𝗮𝗻𝗱 𝗟𝗡𝗣 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀.

• Last but not least, we celebrated a major milestone at ASGCT: 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗵𝘂𝗺𝗮𝗻 𝘁𝗿𝗲𝗮𝘁𝗲𝗱 𝗳𝗼𝗿 𝗮𝗻 𝗶𝗻𝗰𝘂𝗿𝗮𝗯𝗹𝗲 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘂𝘀𝗶𝗻𝗴 𝗯𝗮𝘀𝗲 𝗲𝗱𝗶𝘁𝗶𝗻𝗴.

We are back from #ASGCT2025! Here are our takeaways:

• 𝗥𝗡𝗔-𝗟𝗡𝗣 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝗿𝗲 𝗴𝗮𝗶𝗻𝗶𝗻𝗴 𝗽𝗼𝗽𝘂𝗹𝗮𝗿𝗶𝘁𝘆, with transient mRNA expression and re-dosing increasingly viewed as effective strategies for precise dosage control and enhanced safety.

• Drew Weissman emphasized the 𝘀𝘁𝗿𝗼𝗻𝗴 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗥𝗡𝗔–𝗟𝗡𝗣 𝗮𝗻𝗱 𝗶𝗻 𝘃𝗶𝘃𝗼 𝗖𝗔𝗥-𝗧 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀, which are gaining attention as a potential solution to reduce treatment costs and waiting times.

• 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗟𝗡𝗣 𝗶𝘀 𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗮𝘀 𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗶𝗻 𝘃𝗶𝘃𝗼 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆.

𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗻𝗲𝘅𝘁 #𝗚𝗲𝗻𝗲𝗘𝗱𝗶𝘁𝗶𝗻𝗴 𝗲𝘅𝗽𝗲𝗿𝗶𝗺𝗲𝗻𝘁?


Get high-quality 𝗖𝗮𝘀𝟵 𝗺𝗥𝗡𝗔 and custom 𝘀𝗴𝗥𝗡𝗔 👉🏻 delivered in just a few weeks.

📩 Reach out today: catug.bio/contact?utm_...

Lauren Beech, James Sullivan, Chevaun Morrison-Smith, Stephen Siecinski, Adam Katz, Samuel Mildrum, Mayur Gurnani, Prachi Dhanania, Caitlyn R. Webb, Giuliana C., Pranjali Rumale, Daniel Costa, Marcus I. Gibson, Yaoyu E. Wang, Joe Newman & Thomas McCauley

Image sourced from the article.

The authors stress the versatility, rapid design, and development of programmable mRNA therapeutics. Delivered by LNP, it allows for safe and straightforward clinical applications.

🔵 𝗔𝘁 𝗖𝗔𝗧𝗨𝗚 𝘄𝗲 𝗵𝗲𝗹𝗽 𝘆𝗼𝘂 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗲, 𝘁𝗲𝘀𝘁 𝗮𝗻𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲 𝗰𝘂𝘀𝘁𝗼𝗺 𝗺𝗥𝗡𝗔-𝗟𝗡𝗣 𝗳𝗼𝗿 𝗺𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀.

👉🏻 lnkd.in/dwEBywfj

With just 𝗼𝗻𝗲 𝗺𝗥𝗡𝗔-𝗟𝗡𝗣 𝗱𝗼𝘀𝗲:

✅ 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲𝘅𝗲𝗱 𝘀𝗶𝗹𝗲𝗻𝗰𝗶𝗻𝗴 of gene clusters like CXCL1-8.
✅ 𝗪𝗲𝗲𝗸𝘀 𝘁𝗼 𝗺𝗼𝗻𝘁𝗵𝘀 𝗼𝗳 𝗲𝗳𝗳𝗲𝗰𝘁 via chromatin modification.
✅ Downstream reduction in inflammation, including 𝗶𝗻 𝘃𝗶𝘃𝗼 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗻𝗲𝘂𝘁𝗿𝗼𝗽𝗵𝗶𝗹 𝗺𝗶𝗴𝗿𝗮𝘁𝗶𝗼𝗻.
✅ 𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆 via programmable DNA-binding domains